Navigation Links
Hard To Treat Diseases (HTDS) Set To Acquire Cosmetics Company
Date:1/7/2009

CLEARWATER, FL, Jan. 7 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) www.htdsmedical.com the company is pleased to announce that it has identified a cosmetics company as a potential merger candidate. The cosmetics company also located in E Europe (Serbia) is engaged in online sales of the "Melem" product. Melem is a versatile, all-purpose skin and lip balm. It has a wide variety of skin and lip problems including eczema, psoriasis, chapped skin and lips, calluses, sunburns, insect bites and much more.

Andrea Rubio Zecevic, who currently acts as a head scientific advisor to HTDS said "Just to be clear, the Melem cosmetics company is not the core business of HTDS by any stretch of the imagination. It's a small self supporting cosmetics company and a nice add on for HTDS. The opportunities in this region due to the Balkan wars of the 1990s are enormous. There are various European Union reconstruction programs and enticements in place while the whole country is in the process of privatizing its entire infrastructure. Just to give our readers an example, HTDS will pay for the Melem cosmetics company a sum equivalent to a price of a USA based mid-sized car. This includes all the formulas, packaging the good will, the client base and whole back office. This is a fraction of the reproduction cost had we bought a similar company just 300-400 miles west in Switzerland or Austria or any other western European country. The company will complete the transaction on all cash basis. Currently this region of the world is celebrating the Orthodox Christmas. As soon as these holidays are behind them, we expect the final documents will be executed and the merger company name announced. In addition we are in contact with the Chief Scienist Dr. Sanja Pekovic who will shortly after the holidays commence furnishing us with regular updates on the progress her team has made with their work (see www.slavicabiochem.com for details). Our aspirations for the merger with the Chinese based medical company engaged in the similar research as Slavica continues. The synergies are definitely present. Our representatives will be in Beijing next week and we should have some preliminary news to report on that front as well."

The company will provide further details as they become available.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.

CONTACT: For scientific dialogue and any medical inquiry only please contact Andrea Rubio Zecevic via e-mail at azconsulting2001@gmail.com. For any corporate matters the readers should contact the company directly at corporate@htdsmedical.com

CONTACT: For scientific dialogue and any medical inquiry only please contact Andrea Rubio Zecevic via e-mail at azconsulting2001@gmail.com. For any corporate matters the readers should contact the company directly at corporate@htdsmedical.com


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Warner Chilcott and Dong-A Sign U.S. License Agreement For Erectile Dysfunction Treatment
2. Kawasaki Disease Treated with Plasma-Derived Therapy
3. Unnecessary Spinal Surgery Will Waste Billions of Dollars in 2009 and Patients Will Continue to Suffer Unless the Primary Cause of Most Back Pain is Treated, Says Pain Specialist Norman Marcus, M.D.
4. Galderma Announces Availability of Epiduo(TM) Gel, the First and Only Combination Treatment with a Retinoid and Benzoyl Peroxide to Treat Acne
5. First RapidArc Radiotherapy Treatment in Italy Takes Place at Leading Milan Cancer Center
6. Dr. Mitchell L. Petusevsky, M.D., F.C.C.P. Meets Growing Demand for the Treatment of Sleep and Pulmonary Disorders
7. New Addiction Treatment Program Allows You to Attend Drug Rehabilitation and Still Keep Your Day Job
8. New appropriate use criteria guide treatment of patients with heart blockage
9. Cell death from cytomegalovirus may bring new life to treatment of retinal disease
10. Hard To Treat Diseases (HTDS) Completes E Europe Merger
11. Molecular imaging enables earlier, individualized treatment of thyroid cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... York (PRWEB) , ... April 28, 2017 , ... ... anti-aging skincare and advanced nutraceutical supplements, through its Nova Skin Sciences division, ... the hydrating benefits of a moisturizer with the power of an anti-aging concentrate. ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Rob Lowe ... and now he has leant his presence to an educational purpose as the host ... one important one being cancer. In a recent episode, the series focuses on thyroid ...
(Date:4/28/2017)... ... April 28, 2017 , ... Christie Medical Holdings, Inc. ... alliance with B. Braun Medical Inc. , a leader in infusion therapy and ... with as many as 90 percent of hospital patients receiving a peripheral IV catheter ...
(Date:4/27/2017)... , ... April 27, 2017 , ... ... Insights in Incentives, Rewards, and Recognition: A Nudge Guide," a groundbreaking analysis of ... field. Offering practical takeaways to apply immediately to IRR programs, the report highlights ...
(Date:4/27/2017)... TX (PRWEB) , ... April 27, 2017 , ... ... its all natural deodorant. On the heels of Thinksport’s award-winning sunscreen they’ve used ... non-toxic deodorant that actually works! , Countless deodorants flood the aisles that contain ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017 Research and Markets has announced ... Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive ... offering. ... market was valued at US$ 7,167.6 Mn in 2015, and ... at a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/20/2017)... , April 20, 2017 Research and ... Pharmaceutical Contract Manufacturing Services Market Analysis By Service (Manufacturing, Research), ... Forecasts, 2014 - 2025" report to their offering. ... The Latin American pharmaceutical ... billion by 2025 Low drug registration cost in ...
(Date:4/19/2017)... The Mobile X-Ray product segment is the most ... the forecast period Mobile X-Ray segment is the ... X-Ray devices market, which is estimated to be valued at ... CAGR of 7% over the forecast period. Mobile X-Ray segment ... US$ 100 Mn in 2017 over 2016. The segment,s revenue ...
Breaking Medicine Technology: